FAST-TRACKED BUT FALLING SHORT? THERAPEUTIC VALUE AND POLICY ALIGNMENT OF FDA-APPROVED ANTIBIOTICS, 2010-2025
Author(s)
Rosa Rodriguez-monguio, PhD, MS1, Enrique Seoane-Vazquez, PhD2, John Powers III, MD FACP FIDSA3;
1University of California San Francisco, Professor and Director, San Francisco, CA, USA, 2Chapman University School of Pharmacy, Irvine, CA, USA, 3George Washington University, Washington DC, DC, USA
1University of California San Francisco, Professor and Director, San Francisco, CA, USA, 2Chapman University School of Pharmacy, Irvine, CA, USA, 3George Washington University, Washington DC, DC, USA
OBJECTIVES: U.S. laws have established incentives to encourage development of novel antibiotics. We assessed if systemic antibiotics approved by the FDA since 2010 provided added therapeutic benefit, addressed unmet patient needs, or targeted drug-resistant bacteria. We also evaluated the alignment of federal funding for antibiotics with stated policy objectives.
METHODS: We collected and analyzed data from FDA websites, federal databases, and sponsor company reports.
RESULTS: The FDA approved 23 systemic antibiotics between 2010-2025, all based on non-inferiority designs. All antibiotics were approved using FDA priority review, 73.9% received fast track designation, and 95.7% were granted Qualified Infectious Disease Product designation. None of the antibiotics demonstrated evidence of added clinical value in primary endpoint clinical cure compared to their active controls. Antibiotics were approved for 36 indications (mean 1.3±0.7 indications/antibiotic), including 30.6% for urinary tract infections, 18.4% skin and skin structure infections, and 13.9% community-acquired pneumonia, hospital-acquired pneumonia/ventilator-associated pneumonia, and intra-abdominal infections. Overall, 30.6% indications were approved for patients with limited or no alternative options although none were studied in this population and 11.1% were labeled as based on limited clinical safety and efficacy data. Of all approved indications, 33.3% were supported by evidence from two clinical trials, 58.3% by one trial, and 8.6% of indications were approved without clinical trial evidence. One in four approved indications included methicillin-resistant Staphylococcus aureus (MRSA), although trials were not designed to assess non-inferiority specifically in MRSA. Of the antibiotics approved, 40.9% received federal funding, yet none addressed biothreats, multidrug-resistant bacteria, or unmet patient needs as stated in federal contracts.
CONCLUSIONS: Legislative incentives encouraging development of antibiotics led to more marketing approvals but lacked evidence of added patient benefits, improved outcomes in drug-resistant disease, or addressed unmet patient needs. Incentives need realignment to require demonstrated added patient benefits.
METHODS: We collected and analyzed data from FDA websites, federal databases, and sponsor company reports.
RESULTS: The FDA approved 23 systemic antibiotics between 2010-2025, all based on non-inferiority designs. All antibiotics were approved using FDA priority review, 73.9% received fast track designation, and 95.7% were granted Qualified Infectious Disease Product designation. None of the antibiotics demonstrated evidence of added clinical value in primary endpoint clinical cure compared to their active controls. Antibiotics were approved for 36 indications (mean 1.3±0.7 indications/antibiotic), including 30.6% for urinary tract infections, 18.4% skin and skin structure infections, and 13.9% community-acquired pneumonia, hospital-acquired pneumonia/ventilator-associated pneumonia, and intra-abdominal infections. Overall, 30.6% indications were approved for patients with limited or no alternative options although none were studied in this population and 11.1% were labeled as based on limited clinical safety and efficacy data. Of all approved indications, 33.3% were supported by evidence from two clinical trials, 58.3% by one trial, and 8.6% of indications were approved without clinical trial evidence. One in four approved indications included methicillin-resistant Staphylococcus aureus (MRSA), although trials were not designed to assess non-inferiority specifically in MRSA. Of the antibiotics approved, 40.9% received federal funding, yet none addressed biothreats, multidrug-resistant bacteria, or unmet patient needs as stated in federal contracts.
CONCLUSIONS: Legislative incentives encouraging development of antibiotics led to more marketing approvals but lacked evidence of added patient benefits, improved outcomes in drug-resistant disease, or addressed unmet patient needs. Incentives need realignment to require demonstrated added patient benefits.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
CO174
Topic
Clinical Outcomes
Disease
SDC: Infectious Disease (non-vaccine), STA: Biologics & Biosimilars